Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
We tested the inhibitory power and urinary excretion of several derivatives of hippurohydroxamic acid, including some newly synthesized compounds. m-Methoxyhippurohydroxamic acid (UCD II) strongly inhibited urease activity and high urinary excretion after oral administration to rats. UCD II inhibited the alkalinization of infected urine in vitro and in vivo and prevented bladder stone formation when it was orally administered to rats with urinary tract infection caused by Proteus mirabilis. The clinical application of UCD II to the prevention of pathologic sequelae of urinary infection with urease-producing bacteria awaits evaluation of the safety of the compound.
D000818:Animals; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D008274:Magnesium / Q000378:metabolism; D017616:Magnesium Compounds; D008297:Male; D010710:Phosphates / Q000378:metabolism; D011512:Proteus Infections / Q000150:complications*; D011513:Proteus mirabilis; D000644:Quaternary Ammonium Compounds / Q000378:metabolism; D051381:Rats; D000069877:Struvite; D014510:Urease / Q000037:antagonists & inhibitors*; D001744:Urinary Bladder Calculi / Q000517:prevention & control*; D014552:Urinary Tract Infections / Q000150:complications*
D006877:Hydroxamic Acids; D017616:Magnesium Compounds; D010710:Phosphates; D000644:Quaternary Ammonium Compounds; C026781:hippurohydroxamic acid; C026782:2-methoxyhippurohydroxamic acid; D000069877:Struvite; D014510:Urease; D008274:Magnesium